DBV Technologies (DBVT) Competitors $9.76 -0.11 (-1.06%) Closing price 08/7/2025 03:58 PM EasternExtended Trading$9.76 0.00 (0.00%) As of 08/7/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock DBVT vs. SYRE, AKBA, RCUS, COLL, AVXL, IMNM, ELVN, URGN, IOVA, and MLYSShould you be buying DBV Technologies stock or one of its competitors? The main competitors of DBV Technologies include Spyre Therapeutics (SYRE), Akebia Therapeutics (AKBA), Arcus Biosciences (RCUS), Collegium Pharmaceutical (COLL), Anavex Life Sciences (AVXL), Immunome (IMNM), Enliven Therapeutics (ELVN), Urogen Pharma (URGN), Iovance Biotherapeutics (IOVA), and Mineralys Therapeutics (MLYS). These companies are all part of the "pharmaceutical products" industry. DBV Technologies vs. Its Competitors Spyre Therapeutics Akebia Therapeutics Arcus Biosciences Collegium Pharmaceutical Anavex Life Sciences Immunome Enliven Therapeutics Urogen Pharma Iovance Biotherapeutics Mineralys Therapeutics DBV Technologies (NASDAQ:DBVT) and Spyre Therapeutics (NASDAQ:SYRE) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, profitability, earnings, risk, analyst recommendations, institutional ownership, media sentiment and dividends. Do insiders and institutionals believe in DBVT or SYRE? 71.7% of DBV Technologies shares are held by institutional investors. Comparatively, 80.4% of Spyre Therapeutics shares are held by institutional investors. 1.4% of DBV Technologies shares are held by insiders. Comparatively, 15.4% of Spyre Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Does the media favor DBVT or SYRE? In the previous week, DBV Technologies had 2 more articles in the media than Spyre Therapeutics. MarketBeat recorded 10 mentions for DBV Technologies and 8 mentions for Spyre Therapeutics. Spyre Therapeutics' average media sentiment score of 0.94 beat DBV Technologies' score of -0.46 indicating that Spyre Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment DBV Technologies 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Spyre Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is DBVT or SYRE more profitable? Spyre Therapeutics has a net margin of 0.00% compared to DBV Technologies' net margin of -3,220.49%. Spyre Therapeutics' return on equity of -71.30% beat DBV Technologies' return on equity.Company Net Margins Return on Equity Return on Assets DBV Technologies-3,220.49% -287.15% -138.83% Spyre Therapeutics N/A -71.30%-38.69% Which has stronger valuation and earnings, DBVT or SYRE? DBV Technologies has higher revenue and earnings than Spyre Therapeutics. Spyre Therapeutics is trading at a lower price-to-earnings ratio than DBV Technologies, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDBV Technologies$4.15M64.45-$113.92M-$4.77-2.05Spyre Therapeutics$890K1,032.21-$208.02M-$3.40-4.48 Do analysts prefer DBVT or SYRE? DBV Technologies currently has a consensus price target of $14.75, indicating a potential upside of 51.05%. Spyre Therapeutics has a consensus price target of $53.40, indicating a potential upside of 250.39%. Given Spyre Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Spyre Therapeutics is more favorable than DBV Technologies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score DBV Technologies 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.80Spyre Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 2 Strong Buy rating(s) 3.29 Which has more volatility & risk, DBVT or SYRE? DBV Technologies has a beta of -0.58, suggesting that its stock price is 158% less volatile than the S&P 500. Comparatively, Spyre Therapeutics has a beta of 2.82, suggesting that its stock price is 182% more volatile than the S&P 500. SummarySpyre Therapeutics beats DBV Technologies on 13 of the 17 factors compared between the two stocks. Get DBV Technologies News Delivered to You Automatically Sign up to receive the latest news and ratings for DBVT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding DBVT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DBVT vs. The Competition Export to ExcelMetricDBV TechnologiesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$270.34M$2.98B$5.48B$9.57BDividend YieldN/A2.47%4.00%4.18%P/E Ratio-2.0517.9729.8825.14Price / Sales64.45296.54436.3397.36Price / CashN/A41.8335.9458.58Price / Book3.107.238.105.59Net Income-$113.92M-$54.43M$3.26B$265.48M7 Day Performance8.50%0.22%0.65%1.22%1 Month Performance-7.88%5.59%2.44%0.39%1 Year Performance105.23%9.98%27.59%23.47% DBV Technologies Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DBVTDBV Technologies3.13 of 5 stars$9.77-1.1%$14.75+51.0%+111.0%$270.34M$4.15M-2.0580SYRESpyre Therapeutics2.458 of 5 stars$16.16-0.6%$53.40+230.4%-37.9%$980.08M$890K-4.2973Earnings ReportAnalyst ForecastAKBAAkebia Therapeutics3.8309 of 5 stars$3.76+1.1%$6.75+79.5%+171.2%$977.01M$160.18M-17.90430News CoverageGap DownRCUSArcus Biosciences2.0948 of 5 stars$9.22+0.6%$21.29+131.0%-33.4%$969.91M$258M-2.20500Earnings ReportAnalyst ForecastCOLLCollegium Pharmaceutical4.1042 of 5 stars$31.09+3.4%$43.75+40.7%-4.9%$966.20M$631.45M25.48210News CoverageGap UpAVXLAnavex Life Sciences3.5556 of 5 stars$10.82-3.4%$44.00+306.7%+84.5%$956.67MN/A-19.6740Positive NewsIMNMImmunome1.7203 of 5 stars$10.95+3.4%$23.33+113.1%-20.8%$921.46M$9.04M-3.4440News CoverageEarnings ReportUpcoming EarningsAnalyst ForecastGap UpELVNEnliven Therapeutics2.7452 of 5 stars$18.74+0.1%$41.20+119.9%-17.4%$919.07MN/A-9.7650Upcoming EarningsURGNUrogen Pharma4.6798 of 5 stars$19.88+2.5%$32.86+65.3%+28.5%$896.31M$90.40M-6.25200News CoverageEarnings ReportAnalyst ForecastGap DownIOVAIovance Biotherapeutics4.5833 of 5 stars$2.83+5.6%$12.22+331.9%-64.0%$894.94M$164.07M-2.28500Earnings ReportMLYSMineralys Therapeutics2.4841 of 5 stars$13.03-4.6%$32.25+147.5%+14.1%$890.62MN/A-3.4928Upcoming Earnings Related Companies and Tools Related Companies Spyre Therapeutics Alternatives Akebia Therapeutics Alternatives Arcus Biosciences Alternatives Collegium Pharmaceutical Alternatives Anavex Life Sciences Alternatives Immunome Alternatives Enliven Therapeutics Alternatives Urogen Pharma Alternatives Iovance Biotherapeutics Alternatives Mineralys Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DBVT) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredCrypto bros: Meet your replacementLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredAltucher: Trump’s Great Gain is startingNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredCritical AI announcement set to ignite AI 2.0 A new 100% tariff on imported chips just rattled the tech sector—sending some stocks soaring and others tumbli...Timothy Sykes | SponsoredTrump’s new nightmareAccording to Porter Stansberry and Jeff Brown, a government-led financial mobilization is already reshaping Am...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding DBV Technologies S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share DBV Technologies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
